NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Stock Information for Arcturus Therapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.